Ventracor Content

Frequently Asked Questions

Investor Related FAQs

Q: How do I change my contact details and other account information?

A: To change any of your contact details, contact Ventracor’s share registry –

Link Market Services
Level 12, 680 George Street
Sydney NSW 2000 Australia
Tel: 02 8280 7454
Fax: 02 9287 0309
Outside Australia: 61 2 8280 7454
www.linkmarketservices.com.au

Q: How can I obtain Ventracor announcements to the market?
A: These announcements are available in the News section of Ventracor's website, by accessing the archive section of the Australian Stock Exchange - ASX: VCR or by Contacting Ventracor by email info@ventracor.com, mail or facsimile.

Q: How many Ventracor ordinary paid shares are there?
A: Approximately 300 million ordinary fully paid shares.

Q: What is Ventracor’s ticker symbol and on what exchange do its shares trade?
Ventracor's shares trade under the symbol VCR on the Australian Stock Exchange - ASX: VCR.

American Depository Receipts (ADR)

Ventracor Limited has a Level I American Depositary Receipt (ADR) program in the United States. Level I ADRs trade in the United States over-the-counter (OTC) market and are not listed on any exchange. Ventracor’s ratio of underlying shares to ADRs is 20:1. The company’s ADR program is administered by the Bank of New York on behalf of ventracor.

Questions about American Depository Receipts should be directed to The Bank of New York.

The Bank of New York
Depositary Receipts Division
22nd Floor, 101 Barclay Street
New York New York 10286
United States of America

Toll free number for residents of the United States
1-888-BNY-ADRs

Phone number for non-US residents
+1-610-382-7833
Website www.adrbny.com

Q: Who are the executive and board of Ventracor?

A: The principal officers of the company are:

Peter Crosby, Chief Executive Officer

Graeme Fallet, Chief Financial Officer and Company Secretary

Dr John Woodard, Chief Scientific Officer

Tom Gould, Vice President US Sales & Marketing

Roman Greifeneder, Vice President Techical Operations Sydney

Jeff Lee, Vice President of Quality Assurance and Regulatory Compliance

Robert Petterson, European Business Manager

Helene Zintack , Vice President Clinical Affairs

Camilla Newcombe, Company Secretary and Legal Counsel

The Ventracor Board comprises:

Non-Executive Chairman, John Ward
Managing Director, Peter Crosby
Non-Executive Director, William Curran
Non-Executive Director, Jeff Goodman
Non-Executive Director, Elizabeth Nosworthy AO
Non-Executive Director, Ross Harricks

Q: Can I be included in e-mail alerts?
A: Yes, you may by accessing the News Room.

Q: How can I contact Ventracor Investor Relations?
A: Ventracor Investor Relations:

Telephone In Australia: 02 9406 3100
Outside Australia: 61 2 9406 3100

Facsimile In Australia: 02 9406 3101
Outside Australia: 61 2 9406 3101
Email: info@ventracor.com

Mail:
Ventracor Limited
126 Greville Street
Chatswood NSW 2067
Sydney Australia

Q: When does Ventracor’s fiscal year end?
A: Ventracor’s fiscal year ends 30 June.

Q: Can I obtain Ventracor’s share price movement detail?
A: Yes. Click here to visit the ASX site.

Q: How can I buy Ventracor stock?
A: To buy Ventracor shares, you will need to contact a licensed stockbroker.

Q: When was Ventracor established and where is it located?
A: Ventracor was previously MicroMedical Industries Limited, which was listed on the Australian Stock Exchange in August 1993. Its name change to Ventracor Limited was ratified by a majority of shareholders on 5 July 2002. The company’s headquarters are based in Sydney, Australia.

Q: What is the target market for the VentrAssist® LVAD?
A: The market for LVADs is patients with end stage Congestive Heart Failure (CHF), who have few options.

Q: What is Ventracor’s vision?
A: Ventracor is dedicated to becoming the partner of choice for healthcare professionals to make the VentrAssist® LVAD the standard of care worldwide.

Q: Who is Ventracor Limited?
A: Ventracor is a global medical device company which produces an implantable blood pump, the VentrAssist® Left Ventricular Assist Device (LVAD), as a therapy to improve the lives of heart failure patients and their families.

Disclaimer	\|	Privacy Policy

Ventracor | Ventrassist | Investor Centre | Clinical Trials | News Room

home | contact us | glossary | faqs | sitemap